- PNDRI Employee Spotlight: Meet Jesse Riordan.
Jesse has been a post-doc in Dr Nadeau’s lab for the last 14 months. His project focuses on using mice as a model system to understand the genetics and molecular basis of Non-Alcoholic Fatty Liver Disease (NAFLD). Jesse really likes working at PNDRI: the laid back atmosphere and nimble structure allows scientists to focus on their research. Before joining PNDRI, Jesse completed his PhD on liver cancer genetics at the University of Iowa. His career goal is to be an independent investigator and have his own lab. Interesting fact about Jesse: Jesse used to brew his own beer. Although he has not been doing it since his son Max, 3-year old, was born.
- PNDRI educates.
Dr. Aimee Dudley’s new Genetics paper had been selected by the GENETICS Editors as one of the January 2015 Highlights. This same paper is now featured on the Saccharomyces Genome Database blog, intended to highlight new developments in yeast research for researchers and students from the high school level on up. Very interesting article.
Paul Robertson: “Continuing the JCEM Mission With Its New Editorial Team.” Robertson RP. J Clin Endocrinol Metab 2015 Jan; 100(1): 53-4.
David Galas: “Molecular and Clinical Evidence for an ARMC5 Tumor Syndrome: Concurrent Inactivating Germline and Somatic Mutations Are Associated With Both Primary Macronodular Adrenal Hyperplasia and Meningioma.” Elbelt U, Trovato A, Kloth M, Gentz E, Finke R, Spranger J, Galas D, Weber S, Wolf C, König K, Arlt W, Büttner R, May P, Allolio B, Schneider JG. J Clin Endocrinol Metab. 2015 Jan: 100(1):E119-28.
Aimée Dudley: “Allelic variation, aneuploidy, and nongenetic mechanisms suppress a monogenic trait in yeast.” Sirr A, Cromie GA, Jeffery EW, Gilbert TL, Ludlow CL, Scott AC, Dudley AM. Genetics. 2015 Jan;199(1):247-62.
Jesse Riordan: “Sequencing Methods and datasets to improve functional interpretation of sleeping beauty mutagenesis screens.” Riordan JD, Drury LJ, Smith RP, Brett BT, Rogers LM, Scheetz TE, Dupuy AJ. BMC Genomics, 2014 Dec 19; 15:1150.
Bill Hagopian: “Early Childhood Gut Microbiomes Show Strong Geographic Differences Among Subjects at High Risk for Type 1 Diabetes.” Kemppainen KM, Ardissone AN, Davis-Richardson AG, Fagen JR, Gano KA, León-Novelo LG, Vehik K, Casella G, Simell O, Ziegler AG, Rewers MJ, Lernmark A, Hagopian W, She JX, Krischer JP, Akolkar B, Schatz DA, Atkinson MA, Triplett EW; for the TEDDY Study Group. Diabetes Care. 2014 Dec 17
David Galas: “The extracellular RNA complement of Escherichia coli and its immunostimulatory properties.” Ghosal, A., Upadhyaya, B.B., Fritz, J.V., Heintz-Buschart, A., Wang, K., Desai, M., Dilimulati, Y., Huang, D., Baumuratov, A., Galas, D.J., Wilmes, P. MicrobiologyOpen (in press, Dec 2014)
Bill Hagopian: “Prevalence of obesity was related to HLA-DQ in 2-4 year-old children at genetic risk for type 1 diabetes.” Yang J, Lernmark A, Uusitalo UM, Lynch KF, Veijola R, Winkler C, Larsson HE, Rewers M, She JX, Ziegler AG, Simell OG, Hagopian WA, Akolkar B, Krischer JP, Vehik K; TEDDY Study Group. Int J Obes (Lond) 2014 Dec; 38(12):1491-6.
David Galas: Mutations in STX1B, encoding a presynaptic protein, cause fever-associated epilepsy syndromes. Schubert J, Siekierska A, Langlois M, May P, Huneau C, Becker F, Muhle H, Suls A, Lemke JR, de Kovel CG, Thiele H, Konrad K, Kawalia A, Toliat MR, Sander T, Rüschendorf F, Caliebe A, Nagel I, Kohl B, Kecskés A, Jacmin M, Hardies K, Weckhuysen S, Riesch E, Dorn T, Brilstra EH, Baulac S, Møller RS, Hjalgrim H, Koeleman BP; EuroEPINOMICS RES Consortium, Jurkat-Rott K, Lehman-Horn F, Roach JC, Glusman G, Hood L, Galas DJ, Martin B, de Witte PA, Biskup S, De Jonghe P, Helbig I, Balling R, Nürnberg P, Crawford AD, Esguerra CV, Weber YG, Lerche H. Nat Genet. 2014 Dec;46(12):1327-32.
Seminars and events:
Other great events on WBBA event website.
Matching Grants: program and project – require strategic co-investment by external funders. All applicants must speak with LSDF staff to determine if a pre-proposal may be submitted
Proof Of Concept Grants: intended to enhance the commercial viability of health-related technologies or concepts developed by non-profit organizations or enhance the competitiveness of early-stage companies for private equity investment (maximum award is $250,000 in total costs).
Small Business Innovation Research Grants: Omnibus solicitation of the NIH, CDC, FDA and ACF: Application due dates are April 5th, August 5th and December 5th.
More information on WBBA website.
OTHER INTERESTING NEWS
- Researchers prevent Type 1 diabetes in mouse model.
- BPA exposure during pregnancy causes oxidative stress in child, mother.
- Whole-Exome Sequencing Technology Identifies Drug Resistance Gene in Testicular Cancer.